Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib + GEMOX in Advanced Biliary Cancer
NCT02105350Phase 1Withdrawn
- Sponsor
- University Health Network
- Start
- Jun 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of binimetinib in biliary tract cancer (BTC) and gallbladder cancer, sponsored by University Health Network. Primary endpoints: Total incidence of grade 3 and 4 adverse events at 2 years, Total rate of grade 3 and 4 adverse events at 2 years and 1 more. Planned start Jun 2015; status: withdrawn.
02
Drugs
binimetinib
03
Conditions
biliary tract cancer (BTC)gallbladder cancer
Beyond the preview
Go deeper on NCT02105350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02105350.